Skip to main content Accessibility help
×
Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-23T05:21:30.809Z Has data issue: false hasContentIssue false

Chapter 7 - The Pharmaceutical System and Its Components

Regulation and Management and Associated Challenges

from Section 1 - Analyzing Health Systems: Concepts, Components, Performance

Published online by Cambridge University Press:  08 December 2022

Sameen Siddiqi
Affiliation:
Aga Khan University
Awad Mataria
Affiliation:
World Health Organization, Egypt
Katherine D. Rouleau
Affiliation:
University of Toronto
Meesha Iqbal
Affiliation:
UTHealth School of Public Health, Houston
Get access

Summary

Equitable access to health products is a key condition and an indicator for countries’ progress towards Universal Health Coverage (UHC). Access to healthcare, including essential medicines, is a fundamental human right. Realization of this right involves various combinations of public and private financing and service provision arrangements. The pharmaceutical system is an integral subset of the health system which requires mature regulatory structures and robust supply systems to ensure that health goals are achieved and support country efforts to effectively advance UHC. The landscape of pharmaceutical systems is rapidly changing with increasingly complex technologies, often without clear regulatory approaches or mechanisms to achieve equitable access, especially in low and middle-income countries (L&MICs). Medicines are life-enhancing and lifesaving commodities. For a health system to achieve public health goals, medicines should be available in sufficient quantities and be affordable to the population. Health products must also be safe, quality assured, efficacious and used appropriately to achieve desired health outcomes.

Type
Chapter
Information
Making Health Systems Work in Low and Middle Income Countries
Textbook for Public Health Practitioners
, pp. 102 - 117
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

World Health Organization. The world medicines situation 2011: medicine expenditures. 2011. www.who.int/health-accounts/documentation/world_medicine_situation.pdf (accessed December 12, 2021).Google Scholar
World Health Organization. Public spending on health: a closer look at global trends. 2018. www.who.int/publications/i/item/WHO-HIS-HGF-HFWorkingPaper-18.3 (accessed December 12, 2021).Google Scholar
US Food and Drug Administration. Drugs@FDA glossary of terms. 2017. www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-glossary-terms#M (accessed February 17, 2022).Google Scholar
World Health Organization. Guidelines on clinical evaluation of vaccines: regulatory expectations. 2016. www.who.int/biologicals/BS2287_Clinical_guidelines_final_LINE_NOs_20_July_2016.pdf (accessed February 17, 2022).Google Scholar
European Medicines Agency. Advanced therapy medicinal products: overview. 2022. www.ema.europa.eu/en/human-regulatory/overview/advanced-therapy-medicinal-products-overview (accessed February 17, 2022).Google Scholar
World Health Organization. Safety issues in the preparation of homeopathic medicines. 2009. https://apps.who.int/iris/handle/10665/44238 (accessed February 17, 2022).Google Scholar
World Health Organization. WHO traditional medicine strategy: 2014–2023. 2013. www.who.int/publications/i/item/9789241506096 (accessed February 17, 2022).Google Scholar
US Food and Drug Administration. Biological product definitions. n.d. www.fda.gov/files/drugs/published/Biological-Product-Definitions.pdf (accessed February 17, 2022).Google Scholar
World Health Organization. WHO guidelines on good manufacturing practices for blood establishments. 2011. www.who.int/bloodproducts/publications/GMP_Bloodestablishments.pdf (accessed February 17, 2022).Google Scholar
World Health Organization. Medical devices. 2022. www.who.int/health-topics/medical-devices#tab=tab_1 (accessed February 17, 2022).Google Scholar
United Nations. Sustainable Development Goals. 2021. https://sdgs.un.org/goals/goal3 (accessed October 11, 2021).Google Scholar
World Health Organization. Promoting access to medical technologies and innovation: intersections between public health, intellectual property and trade. 2020. www.wto.org/english/res_e/publications_e/who-wipo-wto_2020_e.htm (accessed October 14, 2021).Google Scholar
Hogerzeil, H. V., Samson, M., Casanovas, J. V., et al. Is access to essential medicines as part of the fulfilment of the right to health enforceable through the courts? Lancet 2006; 368(9532): 305311.Google Scholar
Hogerzeil, H. V.. Essential medicines and human rights: what can they learn from each other? Bull World Health Organ 2006; 84(5): 371375.Google Scholar
Hafner, T., Walkowiak, H., Lee, D., et al. Defining pharmaceutical systems strengthening: concepts to enable measurement. Health Policy Plan 2017; 32(4): 572584.Google Scholar
Peters, D. H., Garg, A., Bloom, G., et al. Poverty and access to health care in developing countries. Ann N Y Acad Sci 2008; 1136: 161171.Google Scholar
World Health Organization. Pharmaceutical system transparency and accountability assessment tool: good governance for medicines – progressing access in the SDG era. 2018. https://apps.who.int/iris/handle/10665/275370 (accessed December 12, 2021).Google Scholar
World Health Organization. Systems thinking for health systems strengthening. 2009. https://apps.who.int/iris/bitstream/handle/10665/44204/9789241563895_eng.pdf?sequence=1 (accessed October 12, 2021).Google Scholar
Bigdeli, M., Jacobs, B., Tomson, G., et al. Access to medicines from a health system perspective. Health Policy Plan 2013; 28(7): 692704.Google Scholar
World Health Organization. How to develop and implement a national drug policy. 2009. www.who.int/management/background_4b.pdf (accessed October 12, 2021).Google Scholar
World Health Organization. List of stringent regulatory authorities. 2021. www.who.int/initiatives/who-listed-authority-reg-authorities/SRAs (accessed October 17, 2021).Google Scholar
World Health Organization. Evaluating and publicly designating regulatory authorities as WHO listed authorities: policy document. 2021. www.who.int/publications/i/item/9789240023444 (accessed October 12, 2021).Google Scholar
Khadem Broojerdi, A., Baran Sillo, H., Ostad Ali Dehaghi, R., et al. The World Health Organization global benchmarking tool: an instrument to strengthen medical products regulation and promote universal health coverage. Front Med 2020; 7: 457.Google Scholar
World Health Organization. WHO Global Benchmarking Tool (GBT) for evaluation of national regulatory systems. 2021. www.who.int/tools/global-benchmarking-tools (accessed October 17, 2021).Google Scholar
Guzman, J., O’Connell, E., Kikule, K., et al. The WHO Global Benchmarking Tool: a game changer for strengthening national regulatory capacity. BMJ Glob Health 2020; 5(8): e003181.Google Scholar
Management Sciences for Health. MDS-3: managing access to medicines and health technologies. 2012. https://msh.org/wp-content/uploads/2014/01/mds3-jan2014.pdf (accessed October 13, 2021).Google Scholar
World Health Organization. Selection of essential medicines at country level: using the WHO model list of essential medicines to update a national essential medicines list. 2020. www.who.int/publications/i/item/9789241515443 (accessed October 11, 2021).Google Scholar
World Health Organization. Signpost: WHO essential medicines. 2021. www.who.int/rhem/signpost/essential_medicines/en (accessed October 17, 2021).Google Scholar
Huff-Rousselle, M.. The logical underpinnings and benefits of pooled pharmaceutical procurement: a pragmatic role for our public institutions? Soc Sci Med 2012; 75(9): 15721580.Google Scholar
World Health Organization. Promoting rational use of medicines: core components. 2002. www.who.int/medicines/publications/policyperspectives/ppm05en.pdf (accessed October 11, 2021).Google Scholar
World Health Organization. Promoting rational use of medicines. 2021. www.who.int/activities/promoting-rational-use-of-medicines/ (accessed October 17, 2021).Google Scholar
European Medicines Agency. Pharmacovigilance: overview. 2021. www.ema.europa.eu/en/human-regulatory/overview/pharmacovigilance-overview (accessed December 27, 2021).Google Scholar
World Health Organization. Ten years in public health, 2007–2017: report by Dr Margaret Chan, Director-General, World Health Organization. 2017. https://apps.who.int/iris/handle/10665/255355 (accessed October 11, 2021).Google Scholar
World Health Organization. Equitable access to essential medicines: a framework for collective action. 2004. https://apps.who.int/iris/handle/10665/68571 (accessed December 27, 2021).Google Scholar
Frost, L. J., Reich, M. R.. How Do Good Health Technologies Get to Poor People in Poor Countries. Boston, MA, Harvard University Press, 2010.Google Scholar
Wagner, A. K., Quick, J. D., Ross-Degnan, D.. Quality use of medicines within universal health coverage: challenges and opportunities. BMC Health Serv Res 2014; 14: 357.Google Scholar
Reidenberg, M. M.. Can the selection and use of essential medicines decrease inappropriate drug use? Clin Pharmacol Ther 2009; 85(6): 581583.Google Scholar
Tremblay, M.. Medicines counterfeiting is a complex problem: a review of key challenges across the supply chain. Curr Drug Saf 2013; 8(1): 4355.Google Scholar
World Health Organization. Using indicators to measure country pharmaceutical situations: fact book on WHO level I and level II monitoring indicators. 2006. www.who.int/medicines/publications/WHOTCM2006.2A.pdf (accessed October 11, 2021).Google Scholar
Sabaté, E., ed., Adherence to Long-Term Therapies: Evidence for Action. Geneva, World Health Organization, 2003. https://apps.who.int/iris/bitstream/handle/10665/42682/9241545992.pdf (accessed October 14, 2021).Google Scholar
Aitken, M., Gorokhovich, L.. Advancing the responsible use of medicines: applying levers for change. 2012. https://ssrn.com/abstract=2222541 (accessed October 17, 2021).Google Scholar
World Health Organization. Substandard and falsified medical products. 2021. www.who.int/health-topics/substandard-and-falsified-medical-products#tab=tab_1 (accessed October 17, 2021).Google Scholar
World Health Organization. WHO global surveillance and monitoring system for substandard and falsified medical products. 2017. www.who.int/publications/i/item/WHO-MVP-EMP-SAV-2019.04 (accessed October 18, 2021).Google Scholar
World Health Organization. Member State mechanism on substandard/spurious/falsely-labelled/falsified/counterfeit medical products. 2017. https://apps.who.int/gb/ebwha/pdf_files/WHA70/A70_23-en.pdf (accessed October 18, 2021).Google Scholar
Vian, T., Kohler, J. C., Forte, G., et al. Promoting transparency, accountability, and access through a multi-stakeholder initiative: lessons from the medicines transparency alliance. J Pharm Policy Pract 2017; 10: 18.Google Scholar
Medicines Transparency Alliance. Welcome to MeTA. 2018. www.medicinestransparency.org/ (accessed October 18, 2021).Google Scholar
World Health Organization. Pharmaceutical human resources assessment tools. 2011. www.who.int/medicines/areas/coordination/amrHRToolEnglish.pdf (accessed October 19, 2021).Google Scholar
International Pharmaceutical Federation (FIP). Pharmacy workforce intelligence: global trends report. 2018. www.fip.org/file/2077 (accessed October 12, 2021).Google Scholar
World Health Organization. Joint FIP/WHO guidelines on good pharmacy practice: standards for quality of pharmacy services. 2011. www.who.int/medicines/services/expertcommittees/pharmprep/CLEAN-Rev1-GPP-StandardsQ-PharmacyServices-QAS10-352_July2010.pdf (accessed October 10, 2021).Google Scholar
Chan, P., Grindrod, K. A., Bougher, D., et al. A systematic review of remuneration systems for clinical pharmacy care services. CPJ/RPC 2008; 141(2): 102112.Google Scholar
Velasquez, G.. The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property. Dev World Bioeth 2014; 14(2): 6774.CrossRefGoogle ScholarPubMed
Musungu, S. F., Oh, C.. The use of flexibilities in TRIPS by developing countries: can they promote access to medicines? 2006. https://apps.who.int/iris/handle/10665/43503 (accessed October 19, 2021).Google Scholar
World Trade Organization. What are intellectual property rights? 2021. www.wto.org/english/tratop_e/trips_e/intel1_e.htm (accessed October 19, 2021).Google Scholar
World Trade Organization. TRIPS and public health. 2021. www.wto.org/english/tratop_e/trips_e/pharmpatent_e.htm (accessed October 20, 2021).Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×